AdminMed

11/19/2025

🚀 New Scientific Publication Validates AdminPatch® Microneedle Technology for Enhanced Migraine Treatment

We're excited to announce a new peer-reviewed publication featuring AdminMed's AdminPatch® microneedle arrays in the book "Technological Innovation in Pharmaceutical Research Vol. 1." The chapter, titled "Microneedle Aided Transdermal Delivery of Antimigraine Drugs," presents groundbreaking research demonstrating how our technology can revolutionize migraine treatment. This study was conducted by researchers from KVSR Siddhartha College of Pharmaceutical Sciences (Vijayawada, India) and BITS-Pilani Hyderabad Campus, with support from DST, Ministry of Science and Technology (Govt. of India) and the British Council, London, UK.

Key Quantitative Benefits Demonstrated:
✅ Up to 7.5-fold Enhancement: AdminPatch 1500 achieved remarkable increases in drug permeation - up to 7.5x for Rizatriptan and 3x for Zolmitriptan compared to passive delivery
✅ Faster Relief: Dramatically reduced lag time from ~20 hours to just 4.17 hours for Rizatriptan delivery, enabling much faster therapeutic onset for migraine sufferers
✅ Precision Engineering: Our arrays demonstrated controlled pe*******on depths from 180μm (AdminPatch 600) to 470μm (AdminPatch 1500), with perfect linear correlation (R² = 0.99)
✅ Enhanced Drug Delivery: Achieved 5-fold increase in steady-state drug flux, ensuring consistent and effective medication delivery
✅ 100% Pe*******on Efficiency: All AdminPatch arrays successfully created microconduits with simple manual application

Why This Matters for Migraine Patients: Current oral migraine medications suffer from poor bioavailability (

The World Economic Forum and Scientific American magazine recognize microneedle technology as one of the top 10 emerging technologies! https://www.weforum.org/agenda/2020/11/2020-top-10-emerging-technologies/

11/16/2025

🔬 New Publication Validates AdminPatch® 1200 for Revolutionary Glucose Monitoring Technology

We are excited to announce a groundbreaking publication from Nanyang Technological University Singapore demonstrating that our AdminPatch® 1200 stainless steel microneedle arrays enable minimally invasive, real-time glucose monitoring through advanced Surface Enhanced Raman Spectroscopy (SERS) technology.

Published in the Proceedings of SPIE, the research by Liu et al. from the School of Chemical and Biomedical Engineering and the School of Biological Sciences at Nanyang Technological University showcases the remarkable capabilities of our microneedle technology for intradermal measurements without drawing blood.

Key Performance Metrics Achieved with AdminPatch® 1200:

✅ Clinical-grade accuracy - RMSE of 3.3 mM for glucose prediction, approaching the clinically desirable 1 mM standard,

✅ Comprehensive measurement range - Successfully monitors glucose from 2.8-72.2 mM (hypoglycemia to severe diabetes),

✅ Minimally invasive depth - Enables measurements at 675 µm below skin surface,

✅ Low power operation - Requires only 5 mW laser power for safe in vivo use,

✅ Rapid results - 10-second measurement time for near real-time monitoring,

✅ Meets ISO/DIS 15197 standards - Achieves international clinical requirements for glucose sensors.

This research demonstrates that our robust AdminPatch® 1200 stainless steel microneedle arrays, when silver-coated, deliver glucose concentration predictions with RMSE values of 3.3 mM - performance comparable to the gold standard while eliminating the need for painful blood draws.

The future of diabetes management is here - minimally invasive, continuous, and accurate.

Read the complete publication: "Surface Enhanced Raman Spectroscopy for Malaria Diagnosis and Intradermal Measurements"

https://www.adminmed.com/files/web/publications/2018-Surface-enhanced-Raman-spectroscopy-for-intradermal-glucose-measurements-Liu.pdf

11/12/2025

🔬 BREAKTHROUGH: Universal Influenza Vaccine Research Published Using AdminPatch® 1200 Microneedle Arrays

We are thrilled to announce pioneering research demonstrating that transdermal vaccination with Matrix-2 Protein Virus-like Particle (M2e VLP) induces robust immunity against influenza A virus - published in Vaccines (2021) by researchers at Mercer University's Vaccine Nanotechnology Laboratory and Georgia State University's Center for Inflammation, Immunity & Infection.

This landmark study by Braz Gomes, D'Sa, Allotey-Babington, Kang, and D'Souza represents a significant breakthrough toward a universal influenza vaccine, targeting the highly conserved M2e protein found across all influenza A strains, thereby eliminating the need for annual vaccine reformulation.

Benefits of AdminPatch® 1200 Transdermal Immunization:

✅ Superior Formulation Characteristics:
* 92% microparticle yield with 84% encapsulation efficiency
* Optimal particle size of 1.85–2.49 μm for enhanced uptake by antigen-presenting cells

✅ Exceptional Viral Protection:
* 10-fold reduction in lung viral titers compared to non-adjuvanted formulations
* Protected mice showed minimal body weight loss (

11/11/2025

Breakthrough Publication: AdminPatch 1500 Enables Revolutionary Minimally-Invasive Immune Monitoring in Prestigious Scientific Reports

We're thrilled to announce a groundbreaking publication in Scientific Reports demonstrating how AdminMed's AdminPatch 1500 stainless steel microneedle arrays are advancing the field of immunological diagnostics and monitoring.

In an impressive international collaboration between the Animal and Plant Health Agency (UK), MIT's Koch Institute for Integrative Cancer Research, Pennsylvania State University, and the University of Aberystwyth, researchers successfully employed our robust AdminPatch 1500 microneedle arrays as sampling microneedles (SMNs) to enable minimally-invasive characterization of chemokine and cytokine profiles in interstitial fluid from dermal reaction sites in BCG-vaccinated cattle.

Key Quantitative Achievements with AdminPatch 1500:

📊 47% biomarker detection rate - Successfully detected 7 of 15 tested cytokines/chemokines (IL-1α, IL-6, IL-1RA, IFN-γ, IL-2, IP-10, CCL2) in interstitial fluid

⏱️ 10-minute rapid sampling - Collected sufficient interstitial fluid for comprehensive analysis with just 10 minutes of application

🎯 1400 μm precision pe*******on - Effectively penetrated bovine skin epidermis to reach the dermis with confirmed complete pe*******on

🔬 20 ng/ml detection sensitivity - Detected immunoglobulin G at ultra-low concentrations, demonstrating exceptional biomarker sensitivity

📈 Statistically significant monitoring - Captured significant increases (P

11/11/2025

Exciting Research Publication: AdminPatch Microneedle Arrays Show Remarkable Results for Enhanced Drug Delivery in Lymphatic Filariasis Treatment

We're thrilled to announce a groundbreaking publication in the Indian Journal of Pharmaceutical Education and Research featuring our AdminPatch microneedle arrays! Researchers from KVSR Siddhartha College of Pharmaceutical Sciences, led by Dr. Jyothirmayee Devineni and Dr. Buchi Naidu Nalluri, have demonstrated exceptional results using our technology for transdermal delivery of ivermectin liposomes.

Key Performance Metrics for AdminPatch Arrays:

📊 AdminPatch 1500 (1.5mm): 32.6-fold increase in drug permeability | 15.9-fold increase in skin drug retention

📊 AdminPatch 1200 (1.2mm): 29-fold increase in drug permeability | 11.4-fold increase in skin drug retention

📊 AdminPatch 900 (0.9mm): 24-fold increase in drug permeability | 10.5-fold increase in skin drug retention

📊 AdminPatch 600 (0.6mm): 12.7-fold increase in drug permeability | 6.1-fold increase in skin drug retention

This research demonstrates that AdminPatch microneedle-assisted transdermal drug delivery may bridge the critical need for patient-friendly single drug treatment for lymphatic filariasis, potentially revolutionizing current mass drug administration protocols. The technology enables targeted delivery of

11/10/2025

🚀 Exciting Publication Alert: AdminPatch 900 Microneedles Demonstrate Exceptional Drug Delivery Capabilities

We're thrilled to announce the publication of groundbreaking research featuring our AdminPatch 900 stainless steel microneedle arrays in the prestigious European Journal of Pharmaceutics and Biopharmaceutics!

This collaborative study, led by researchers from De Montfort University (UK), Aristotle University of Thessaloniki (Greece), Brunel University London, Nottingham Trent University, International Hellenic University, and University of Ulster, showcases the remarkable versatility of our microneedle technology for advanced drug delivery applications.

Key Performance Highlights of AdminPatch 900:

📍 Optimal Pe*******on: 800 μm-tall needles achieve 381 μm skin pe*******on depth with just 40N force, effectively reaching the dermis,

⚡ Dual Release Capability: Enables both rapid (100% in 2 hours) and sustained (100% over 7 days) drug release profiles,

🎯 High-Density Design: 900 microneedles per cm² maximize drug delivery efficiency,

💊 Superior Drug Loading: Achieves 94% drug release within 30 minutes for rapid formulations,

🔬 Proven Stability: Coatings maintain integrity for 10+ days, ensuring reliable shelf-life,

🏥 Medical-Grade Quality: SS316L stainless steel construction ensures biocompatibility and mechanical robustness.

This research demonstrates the unique capability of our microneedle arrays to encapsulate diverse drugs within polymeric matrices using electrohydrodynamic atomization, opening doors to personalized medicine and advanced therapeutic delivery systems.

Read the full paper: "Electrospinning/electrospraying coatings for metal microneedles: A design of experiments (DOE) and quality by design (QbD) approach"

http://www.adminmed.com/files/web/publications/2020-Electrospinning-electrospraying-coatings-for-metal-microneedles-Ahmad.pdf

🚀 Exciting Publication Alert: AdminPatch 900 Microneedles Demonstrate Exceptional Drug Delivery Capabilities

We're thrilled to announce the publication of groundbreaking research featuring our AdminPatch 900 stainless steel microneedle arrays in the prestigious European Journal of Pharmaceutics and Biopharmaceutics!

This collaborative study, led by researchers from De Montfort University (UK), Aristotle University of Thessaloniki (Greece), Brunel University London, Nottingham Trent University, International Hellenic University, and University of Ulster, showcases the remarkable versatility of our microneedle technology for advanced drug delivery applications.

Key Performance Highlights of AdminPatch 900:

📍 Optimal Pe*******on: 800 μm-tall needles achieve 381 μm skin pe*******on depth with just 40N force, effectively reaching the dermis,

⚡ Dual Release Capability: Enables both rapid (100% in 2 hours) and sustained (100% over 7 days) drug release profiles,

🎯 High-Density Design: 900 microneedles per cm² maximize drug delivery efficiency,

💊 Superior Drug Loading: Achieves 94% drug release within 30 minutes for rapid formulations,

🔬 Proven Stability: Coatings maintain integrity for 10+ days, ensuring reliable shelf-life,

🏥 Medical-Grade Quality: SS316L stainless steel construction ensures biocompatibility and mechanical robustness.

This research demonstrates the unique capability of our microneedle arrays to encapsulate diverse drugs within polymeric matrices using electrohydrodynamic atomization, opening doors to personalized medicine and advanced therapeutic delivery systems.

Read the full paper: "Electrospinning/electrospraying coatings for metal microneedles: A design of experiments (DOE) and quality by design (QbD) approach"

http://www.adminmed.com/files/web/publications/2020-Electrospinning-electrospraying-coatings-for-metal-microneedles-Ahmad.pdf

11/07/2025

🚀 BREAKTHROUGH RESEARCH: AdminPatch® Microneedles Enable 29-Fold Enhancement in Alzheimer's Transdermal Drug Delivery

We're excited to share groundbreaking research published in the Journal of Drug Delivery Science and Technology demonstrating how our AdminPatch® microneedle arrays are revolutionizing drug delivery for Alzheimer's disease (AD) treatment.

The Challenge: Alzheimer's disease affects millions worldwide, causing progressive cognitive decline due to cholinergic dysfunction. While donepezil (DNP) improves patient outcomes, oral administration presents significant challenges:

* Patients with impaired cognitive function struggle with medication compliance

* Risk of overdosing or skipping doses

* Gastric side effects and non-specific interactions with peripheral nerves

* Need for daily pill management

The Innovation: Researchers at the National Institute of Technology Karnataka and Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, developed pH-sensitive niosomes loaded with donepezil and demonstrated successful transdermal delivery using our AdminPatch® microneedle arrays.

Remarkable Results:

✅ 29-fold enhancement: AdminPatch 1200 achieved a 26.46-fold increase in transdermal permeation compared to passive delivery

✅ Consistent delivery: Steady flux rate of 9.89 ± 0.923 μg/cm²/h for intact niosomes carrying donepezil

✅ Superior drug transport: MN1200 delivered 608.19 ± 15.6 μg of donepezil over 24 hours vs. only 23.43 ± 3.57 μg with passive delivery

✅ Enhanced permeability: Permeability coefficient of 995.15 × 10⁻⁵ cm/h with MN1200 vs. 24.40 × 10⁻⁵ cm/h passive delivery

✅ pH-responsive release: Smart niosomes maintain 82.15% ± 1.54% encapsulation efficiency and release drug in response to brain acidosis associated with AD

✅ Scalable options: Three needle lengths (AdminPatch 600, 777, and 1200) provide flexibility for optimized delivery

Why This Matters: This user-friendly transdermal approach offers a pragmatic alternative for AD patients with cognitive impairment, eliminating the need for daily oral medication while:

* Reducing gastric side effects

* Ensuring consistent drug delivery

* Enabling potential caregiver administration

* Improving patient compliance and quality of life

The Future of Alzheimer's Treatment: By combining our proven AdminPatch® microneedle technology with innovative nanocarrier systems, we're paving the way for more effective, patient-friendly treatments for neurodegenerative diseases.

📄 Read the full publication:

http://www.adminmed.com/files/web/publications/2020-Tailoring-solulan-C24-based-niosomes-for-transdermal-delivery-of-donepezil-Raval+.pdf

Congratulations to the research team at NITK and Manipal Academy for this outstanding contribution to Alzheimer's disease therapeutics!

11/06/2025

🔬 New Scientific Publication: Breakthrough in Dermatological Gene Therapy

We're pleased to announce a significant scientific publication from researchers at the University of Liège (Belgium) demonstrating the exceptional capabilities of our AdminStamp® microneedle array devices for delivering therapeutic genes and macromolecules into the deepest layers of skin.

Published in the International Journal of Pharmaceutics (Volume 572, 2019), lead author C. Bellefroid and colleagues evaluated AdminStamp devices for dermatological gene therapy applications, including delivery of plasmid DNA and siRNA.

Key Quantitative Benefits Demonstrated:

✓ Depth-Dependent Pe*******on Control: AdminStamp 1500 (1400μm needles) successfully delivered nanovectors into the dermis layer, AdminStamp 900 (800μm needles) achieved intermediate depth pe*******on into viable epidermis, while AdminStamp 600 (500μm needles) enabled controlled upper epidermis delivery

✓ 24-Hour Optimal Delivery Window: Maximum fluorescence intensity and deepest skin pe*******on were achieved after 24 hours of application, compared to minimal pe*******on at 3-6 hours

✓ Complete Stratum Corneum Bypass: All three AdminStamp devices (600, 900, and 1500) successfully created microchannels that completely bypassed the stratum corneum barrier, enabling immediate access to viable epidermis–impossible with topical application alone

✓ Enhanced Formulation Synergy: When AdminStamp 1500 was combined with cationic ethosomes containing 25% ethanol and sodium cholate, the deepest pe*******on reaching from viable epidermis to upper dermis was achieved–unattainable with any single enhancement technique

✓ Charge-Selective Enhancement: Cationic formulations delivered via microneedles showed significantly higher fluorescence intensity and pe*******on depth compared to neutral or anionic formulations, demonstrating up to 100% selectivity for positively charged nanovectors

Future Therapeutic Applications:

The authors conclude that this combination approach could be "a promising approach to further deliver efficiently macromolecules such as genes into the skin," positioning AdminStamp devices as a platform technology for various dermatological gene therapies.

Full Citation: C. Bellefroid, A. Lechanteur, B. Evrard, D. Mottet, F. Debacq-Chainiaux, G. Piel, "In vitro skin pe*******on enhancement techniques: A combined approach of ethosomes and microneedles," International Journal of Pharmaceutics, Volume 572, 2019, 118793.

📄 Read the full publication:

https://www.adminmed.com/files/web/publications/2019-In-vitro-skin-pe*******on-enhancement-techniques-A-combined-approach-of-ethosomes-and-microneedles-Piel.pdf

11/04/2025

🔬 Pioneering Research: AdminPen™ Delivers Breakthrough in Rheumatoid Arthritis Treatment!

We're excited to share a groundbreaking publication in the Journal of Drug Delivery Science and Technology showcasing our AdminPen™ 1200 technology in a revolutionary approach to rheumatoid arthritis management!

This landmark study by Zewail et al. (2025) from Harvard Medical School, Damanhour University, and Cairo University, presents the FIRST-EVER report of using hollow microneedle arrays to deliver Pluronic F127 nanohybrid hydrogels loaded with chondroitin sulphate-coated nanostructured lipid carriers containing pomegranate extract in an antigen-induced arthritis (AIA) rat model.

Exceptional in vivo results obtained with AdminPen™ 1200 hollow microneedle array injection devices:

✅ 100% pe*******on efficiency - All 43 hollow microneedles achieved complete skin pe*******on, ensuring reliable intradermal drug delivery to inflamed joints,

✅ Precise 1100-1200 μm pe*******on depth - Optimal breach of skin barriers for direct therapeutic delivery to target tissues,

✅ 75% reduction in TNF-α inflammatory markers - Achieved 42.6 pg/ml vs 173.5 pg/ml in untreated controls, demonstrating powerful anti-inflammatory action,

✅ 65% decrease in joint degradation (MMP-3) - Reduced to 10 Ng/ml from 29.2 Ng/ml, protecting against cartilage breakdown,

✅ Complete joint healing in 14 days - Full resolution of swelling with joint diameters normalized to healthy controls.

This pioneering research establishes AdminPen™ as a game-changing platform for minimally invasive, sustained-release therapies for the treatment of rheumatoid arthritis. By combining advanced nanomedicine with our hollow microneedle technology, we're opening new frontiers in targeted joint therapy with enhanced patient comfort and compliance.

Read the full publication:https://www.adminmed.com/files/web/publications/2025-Intradermal-delivery-of-nanohybrid-thermosensitive-hydrogels-loaded-with-chondroitin-sulphate-Zewail.pdf

11/03/2025

🔬 Groundbreaking Research: AdminPen™ Enables First-Ever Intradermal Delivery of Novel Psoriasis Treatment
We're thrilled to announce a landmark publication in the European Journal of Pharmaceutics and Biopharmaceutics featuring our AdminPen™ 1200 hollow microneedle array technology!
Researchers from Harvard Medical School, Damanhour University, and Cairo University have achieved a world first: the successful intradermal delivery of teriflunomide-loaded emulsomes (TER-EMLs) for the management of psoriasis using hollow microneedle arrays. This pioneering study by Zewail et al. (2025) demonstrates the transformative potential of our AdminPen™ technology in revolutionizing psoriasis treatment.
Key Quantitative Benefits of AdminPen™ 1200 hollow microneedle array injection devices demonstrated:
✅ 100% pe*******on efficiency - All 43 hollow microneedles achieved complete skin pe*******on, creating corresponding dermal micropores for reliable drug delivery,
✅ Optimal 1100-1200 μm pe*******on depth - Effectively breaches stratum corneum and epidermis layers for direct intradermal therapeutic delivery,
✅ Superior inflammatory control - Achieved near-normal NF-KB levels (1.03 vs 0.95 ng/g in controls) compared to 4.8-fold increase in untreated psoriatic tissue,
✅ 3.5-fold antioxidant preservation - Maintained GSH levels at 4.7 pg/g tissue versus only 1.34 pg/g in positive controls
✅ Minimally invasive design - 1200 μm needle height with off-centered hollow pores ensures painless pe*******on and continuous drug flow.
This research validates AdminPen™ hollow microneedle array injection device as an enabling platform for next-generation dermatological therapeutics, offering patients a minimally invasive alternative to conventional psoriasis treatments with enhanced efficacy and reduced side effects.
Read the full paper:https://www.adminmed.com/files/web/publications/2025-Intradermal-delivery-of-teriflunomide-loaded-emulsomes-using-hollow-microneedles-Zewail.pdf
hashtag hashtag hashtag hashtag hashtag hashtag hashtag hashtag hashtag hashtag

10/31/2025

🚀 Breakthrough Research: AdminPen™ 1200 Revolutionizes Psoriasis Treatment Through Advanced Hollow Microneedle Array Injection Technology! 🚀
We're proud to share that our AdminPen™ 1200 hollow microneedle array injection devices have been featured in groundbreaking research published in the Journal of Drug Targeting, demonstrating exceptional performance in photodynamic therapy for the treatment of psoriasis.
Researchers from Damanhour University in Egypt and Cairo University successfully utilized our AdminPen™ 1200 hollow microneedle array injection technology to deliver hypericin-loaded nanocarriers for the non-invasive management of psoriasis, achieving remarkable therapeutic outcomes.
Outstanding Performance Metrics of AdminPen™ 1200:
✅ 100% Puncture Success Rate - All 43 hollow microneedles successfully created microchannels in human skin, ensuring reliable and consistent drug delivery,
📊 1480 μm Deep Drug Distribution - Achieved nearly 2X deeper drug pe*******on compared to conventional methods (750 μm), enabling therapeutic agents to reach critical skin layers,
🎯 43 High-Density Microneedles in 1 cm² - Optimal array configuration provides comprehensive coverage for efficient intradermal delivery across treatment sites,
📏 1200 μm Precision-Engineered Needles - Ideal length successfully bypasses skin barriers while enabling enhanced drug distribution beyond insertion depth,
💊 Superior Clinical Outcomes - Achieved 4.48-fold reduction in inflammatory markers and normalized antioxidant levels comparable to healthy controls when combined with photodynamic therapy
This research validates AdminPen™ 1200 as a game-changing platform for targeted dermal drug delivery, offering painless, efficient, and highly effective treatment options for challenging skin conditions.
The future of minimally invasive therapeutic delivery is here! 💉✨
📄 Read the full paper: "Combined photodynamic therapy and hollow microneedle approach for effective non-invasive delivery of hypericin" - Journal of Drug Targeting, 2024
https://www.adminmed.com/files/web/publications/2024-Combined-photodynamic-therapy-and-hollow-microneedles-Abbas.pdf